share_log

Smart Money Is Betting Big In MRNA Options

Benzinga ·  02:32

Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 48 extraordinary options activities for Moderna. This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 35% leaning bullish and 50% bearish. Among these notable options, 36 are puts, totaling $7,149,868, and 12 are calls, amounting to $827,264.

What's The Price Target?

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $135.0 for Moderna, spanning the last three months.

Volume & Open Interest Trends

In today's trading context, the average open interest for options of Moderna stands at 2268.03, with a total volume reaching 22,831.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $30.0 to $135.0, throughout the last 30 days.

Moderna Option Volume And Open Interest Over Last 30 Days

bigjpg

Noteworthy Options Activity:

SymbolPUT/CALLTrade TypeSentimentExp. DateAskBidPriceStrike PriceTotal Trade PriceOpen InterestVolume
MRNAPUTSWEEPNEUTRAL01/16/26$70.45$70.45$70.45$120.00$2.4M980346
MRNAPUTSWEEPBEARISH01/16/26$70.9$69.7$70.4$120.00$971.5K980346
MRNAPUTSWEEPBULLISH12/18/26$42.15$41.0$41.12$85.00$479.4K1.1K517
MRNAPUTSWEEPBEARISH01/16/26$70.35$69.7$70.35$120.00$443.2K980564
MRNAPUTSWEEPBEARISH12/18/26$82.85$81.3$82.85$130.00$314.8K620290

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna's Current Market Status

  • With a volume of 7,492,117, the price of MRNA is down -6.64% at $46.94.
  • RSI indicators hint that the underlying stock may be oversold.
  • Next earnings are expected to be released in 104 days.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment